A Systematic Review of Efficacy in Irritable Bowel Syndrome: How the Number Needed to Treat May be a Misleading Metric
When standardized endpoints are used, the NNTs for included IBS pharmacotherapies are similar across indications. Failure to account for endpoint heterogeneity in clinical trials for IBS may distort comparative effectiveness conclusions, undermining clinical decision-making.
Authors
- Jonathan A. Busam (ORCID: https://orcid.org/0000-0002-1905-5170)
- Nisha Batta (ORCID: https://orcid.org/0000-0002-0239-8054)
- Ali Rezaie
- Mark Pimentel
Institutions
- Cedars-Sinai Medical Center (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.14309/ajg.0000000000003968
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00